Data as of Dec 19
| +3.85 / +0.91%|
Regeneron Pharmaceuticals, Inc. operates as a biopharmaceutical company. It discovers, invents, develops, manufactures, and commercializes medicines for the treatment of serious medical conditions. Regeneron markets medicines for eye diseases, colorectal cancer and a rare inflammatory condition and has product candidates in development in other areas of high unmet medical need, including hypercholesterolemia, oncology, rheumatoid arthritis, asthma and atopic dermatitis. The company's products include EYLEA (aflibercept) injection, which is used for the treatment of neovascular age related macular degeneration; ARCALYST (rilonacept), which is used for the treatment of Cryopyrin-Associated Periodic Syndrome, including Familial Cold Auto-inflammatory Syndrome and Muckle-Wells Syndrome; and ZALTRAP (ziv-aflibercept) Injection for Intravenous Infusion. It has active research and development programs in many disease areas, including ophthalmology, inflammation, cancer, and hypercholesterolemia. The company was founded by Alferd G. Gilman, Leonard S. Schleifer and Eric M. Shooter on January 8, 1988 and is headquartered in Tarrytown, NY.
|Leonard S. Schleifer||President, Chief Executive Officer & Director|
|Robert E. Landry||Chief Financial Officer|
|George Damis Yancopoulos||Director & Chief Scientific Officer|
|Neil Stahl||Senior VP-Research & Development Sciences|
|William G. Roberts||VP-Regulatory Development & Medical Safety|